Shanghai - Delayed Quote CNY

Beijing Hotgen Biotech Co., Ltd. (688068.SS)

109.40
-0.20
(-0.18%)
At close: 3:00:02 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
488,016.77
510,900.04
547,836.20
3,556,551.57
5,369,203.76
Cost of Revenue
229,669.18
228,067.90
234,873.50
1,646,278.96
2,172,495.47
Gross Profit
258,347.59
282,832.14
312,962.70
1,910,272.61
3,196,708.29
Operating Expense
408,544.76
404,792.50
313,359.50
671,102.75
524,826.61
Operating Income
-150,197.16
-121,960.37
-396.80
1,239,169.86
2,671,881.68
Net Non Operating Interest Income Expense
31,871.95
32,291.64
38,467.88
28,544.77
11,144.08
Pretax Income
-217,086.07
-187,873.68
14,986.95
1,075,220.68
2,581,811.82
Tax Provision
6,950.16
8,064.98
-1,727.23
150,103.69
379,435.14
Net Income Common Stockholders
-220,067.60
-191,004.57
28,922.43
944,736.63
2,185,763.39
Basic EPS
-2.44
-2.12
0.33
10.33
23.75
Diluted EPS
-2.44
-2.12
0.32
10.28
23.75
Basic Average Shares
92,119.57
90,096.49
87,643.74
91,455.63
92,032.14
Diluted Average Shares
92,119.57
90,096.49
90,382.60
91,900.45
92,032.14
Total Operating Income as Reported
-215,061.47
-185,589.82
18,692.30
1,090,853.30
2,584,418.95
Total Expenses
638,213.94
632,860.40
548,233
2,317,381.71
2,697,322.09
Net Income from Continuing & Discontinued Operation
-220,067.60
-191,004.57
28,922.43
944,736.63
2,185,763.39
Normalized Income
-146,280.42
-128,543.01
32,801.79
1,104,085.50
2,275,947.85
Interest Income
32,348.75
32,848.35
39,589.69
31,119.79
12,497.84
Interest Expense
--
449.07
1,008.80
2,318.28
1,272.81
Net Interest Income
31,871.95
32,291.64
38,467.88
28,544.77
11,144.08
EBIT
-215,661.41
-187,424.61
15,995.75
1,077,538.96
2,583,084.63
EBITDA
-215,661.41
-96,662.56
86,524.41
1,197,829.27
2,703,044.50
Reconciled Cost of Revenue
229,669.18
228,067.90
234,873.50
1,646,278.96
2,172,495.47
Reconciled Depreciation
--
90,762.05
70,528.67
120,290.31
68,341.82
Net Income from Continuing Operation Net Minority Interest
-220,067.60
-191,004.57
28,922.43
944,736.63
2,185,763.39
Total Unusual Items Excluding Goodwill
-122,978.64
-83,282.08
-5,172.48
-185,203.82
-105,721.83
Total Unusual Items
-122,978.64
-83,282.08
-5,172.48
-185,203.82
-105,721.83
Normalized EBITDA
-92,682.77
-13,380.48
91,696.90
1,383,033.08
2,808,766.33
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-49,191.46
-20,820.52
-1,293.12
-25,854.95
-15,537.38
12/31/2021 - 9/30/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

25I.SG ImmuPharma PLC
0.0265
-10.17%
 
BSFAF BSF Enterprise Plc
0.0584
0.00%
 
BT3.BE Lineage Cell Therapeutics Inc
0.4060
+5.73%
 
688428.SS InnoCare Pharma Limited
20.56
+0.54%
 
328.SG MeiraGTx Holdings PLC
4.7600
-0.83%
 
6XC.F Soleno Therapeutics, Inc.
64.85
+1.25%
 
22Z.SG Zealand Pharma A/S
56.18
-6.30%
 
XUPB.F Genfit S.A.
3.7800
-0.53%
 
688266.SS Suzhou Zelgen Biopharmaceuticals Co.,Ltd.
99.49
+4.18%
 
GNFTF Genfit S.A.
3.5400
0.00%